Table 1 Baseline characteristics of study sample
|  | Overall (N = 3738) | <  60 year-old (n = 3081) | ≥ 60 year-old (n = 657) | p |
|---|---|---|---|---|
Age (years) | 48.78 ± 11.50 | 45.53 ± 9.88 | 64.08 ± 3.48 | <  0.001 |
Sex, female (%) | 1527 (40.9%) | 1287 (41.8%) | 240 (36.5%) | 0.013 |
Body mass index (kg/m2) | 23.05 ± 3.52 | 22.97 ± 3.61 | 23.41 ± 3.05 | 0.001 |
Cause of ESRD, n (%) |  |  |  | <  0.001 |
 Diabetes mellitus | 870 (23.3%) | 642 (20.8%) | 228 (34.7%) |  |
 Hypertension | 612 (16.4%) | 486 (15.8%) | 126 (19.2%) |  |
 Glomerulonephritis | 1251 (33.5%) | 1121 (36.4%) | 130 (19.8%) |  |
 ADPKD | 172 (4.6%) | 137 (4.4%) | 35 (5.3%) |  |
 Others | 123 (3.3%) | 103 (3.3%) | 20 (3.0%) |  |
 Unknown | 710 (19.0%) | 592 (19.2%) | 118 (18.0%) |  |
Duration of dialysis (months) | 56.17 ± 64.13 | 47.29 ± 62.77 | 50.73 ± 61.03 | 0.201 |
Diabetes mellitus, n (%) | 1073 (28.7%) | 778 (25.3%) | 295 (44.9%) | <  0.001 |
Hypertension, n (%) | 3334 (89.2%) | 2719 (88.3%) | 615 (93.6%) | <  0.001 |
Cardiovascular disease, n (%) | 404 (10.8%) | 260 (8.4%) | 144 (22.0%) | <  0.001 |
Hemoglobin (g/dL) | 10.73 ± 1.58 | 10.70 ± 1.59 | 10.88 ± 1.52 | 0.006 |
Creatinine, baseline (mg/dL) | 8.79 ± 3.36 | 8.96 ± 3.42 | 8.01 ± 2.98 | <  0.001 |
Creatinine, discharge (mg/dL) | 1.22 ± 0.78 | 1.22 ± 0.79 | 1.21 ± 0.69 | 0.708 |
Albumin (g/dL) | 3.93 ± 0.52 | 3.93 ± 0.53 | 3.89 ± 0.49 | 0.049 |
Re-transplantation, n (%) | 289 (7.7%) | 249 (8.1%) | 40 (6.1%) | 0.082 |
Donor age (years) | 46.44 ± 13.18 | 45.47 ± 12.78 | 50.95 ± 14.05 | <  0.001 |
Donor sex, female (%) | 1720 (46.0%) | 1437 (46.7%) | 283 (43.1%) | 0.095 |
Deceased donor, n (%) | 1446 (38.7%) | 1111 (36.1%) | 335 (51.0%) | <  0.001 |
Desensitization, n (%) | 845 (22.6%) | 723 (23.5%) | 122 (18.6%) | 0.006 |
ABO incompatibility, n (%) | 586 (15.7%) | 495 (16.1%) | 91 (13.9%) | 0.156 |
Presence of DSA, n (%) | 230 (6.2%) | 184 (6.0%) | 46 (7.0%) | 0.319 |
Length of hospitalization after KT (days) | 17.88 ± 10.63 | 17.53 ± 10.35 | 19.56 ± 11.71 | <  0.001 |
Induction immunosuppression |  |  |  | <  0.001 |
No use, n (%) | 66 (1.8%) | 52 (1.7%) | 14 (2.1%) | Â |
 Basiliximab, n (%) | 2924 (78.2%) | 2447 (79.4%) | 477 (72.8%) |  |
 ATG, n (%) | 668 (17.9%) | 513 (16.7%) | 155 (23.7%) |  |
 Basiliximab + ATG, n (%) | 77 (2.1%) | 68 (2.2%) | 9 (1.4%) |  |
Calcineurin inhibitors, n (%) | Â | Â | Â | 0.067 |
 No use | 45 (1.2%) | 32 (1.0%) | 13 (2.0%) |  |
 Tacrolimus | 3568 (95.5%) | 2952 (95.8%) | 616 (94.0%) |  |
 Cyclosporine | 122 (3.3%) | 96 (3.1%) | 26 (4.0%) |  |
Mycophenolate, n (%) | 3399 (90.9%) | 2819 (91.5%) | 580 (88.7%) | 0.021 |
mTOR inhibitors, n (%) | 48 (1.3%) | 37 (1.2%) | 11 (1.7%) | 0.324 |
Steroid, n (%) | 3647 (97.6%) | 3011 (97.2%) | 636 (97.2%) | 0.430 |
Follow-up duration (months) | 27.45 ± 12.47 | 27.95 ± 12.41 | 25.14 ± 12.49 | <  0.001 |
Early post-transplant infection, n (%) | 670 (17.9%) | 521 (16.9%) | 149 (22.7%) | <  0.001 |